Optiver Holding’s Harmony Biosciences HRMY Stock Holding History

Optiver Holding’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-276	Closed	-$7.61K	–	2688
2025 Q3	$7.61K	Buy	+276	New	+$9.51K	﹤0.01%	1460

Other funds holding HRMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Optiver Holding's HRMY Position: Q4 2025 in Review

Optiver Holding sold out of Harmony Biosciences (HRMY) in Q4 2025, closing a stake of 276 shares — an estimated $7.61K sold.

Optiver Holding first reported a position in HRMY in Q3 2025 and held it in 1 quarter. The position peaked at $7.61K in Q3 2025. 323 funds tracked by Wall St. Rank hold HRMY as of Q4 2025.

Optiver Holding reported no remaining Harmony Biosciences position as of Q4 2025 after selling out during the quarter.
Optiver Holding sold 276 Harmony Biosciences shares in Q4 2025, an estimated $7.61K.
Optiver Holding first reported a position in Harmony Biosciences in Q3 2025 and held it in 1 quarter.
Optiver Holding's Harmony Biosciences position peaked at $7.61K in Q3 2025.
323 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2025.

Based on Optiver Holding's 13F filing for Q4 2025, filed 17 Feb 2026.